135 related articles for article (PubMed ID: 37917181)
1. Effect of Buffer pH and Concentration on the Dissolution Rates of Sodium Indomethacin-Copovidone and Indomethacin-Copovidone Amorphous Solid Dispersions.
Chiang CW; Tang S; Mao C; Chen Y
Mol Pharm; 2023 Dec; 20(12):6451-6462. PubMed ID: 37917181
[TBL] [Abstract][Full Text] [Related]
2. Generality of Enhancing the Dissolution Rates of Free Acid Amorphous Solid Dispersions by the Incorporation of Sodium Hydroxide.
Zhang HJ; Chiang CW; Maschmeyer-Tombs T; Conklin B; Napolitano JG; Lubach JW; Nagapudi K; Mao C; Chen Y
Mol Pharm; 2024 Jun; ():. PubMed ID: 38836777
[TBL] [Abstract][Full Text] [Related]
3. Effect of Counterions on Dissolution of Amorphous Solid Dispersions Studied by Surface Area Normalized Dissolution.
Chen Y; Lubach JW; Tang S; Narang AS
Mol Pharm; 2021 Sep; 18(9):3429-3438. PubMed ID: 34338529
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
5. Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.
Saboo S; Mugheirbi NA; Zemlyanov DY; Kestur US; Taylor LS
J Control Release; 2019 Mar; 298():68-82. PubMed ID: 30731151
[TBL] [Abstract][Full Text] [Related]
6. Does Media Choice Matter When Evaluating the Performance of Hydroxypropyl Methylcellulose Acetate Succinate-Based Amorphous Solid Dispersions?
Bapat P; Paul S; Thakral NK; Tseng YC; Taylor LS
Mol Pharm; 2023 Nov; 20(11):5714-5727. PubMed ID: 37751517
[TBL] [Abstract][Full Text] [Related]
7. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S; Kestur US; Flaherty DP; Taylor LS
Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677
[TBL] [Abstract][Full Text] [Related]
8. Inhomogeneous Phase Significantly Reduces Oral Bioavailability of Felodipine/PVPVA Amorphous Solid Dispersion.
Gao D; Zhu D; Zhou X; Dong S; Chen Y
Mol Pharm; 2023 Jan; 20(1):409-418. PubMed ID: 36529939
[TBL] [Abstract][Full Text] [Related]
9. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
10. Dissolution Mechanisms of Amorphous Solid Dispersions: Role of Drug Load and Molecular Interactions.
Deac A; Qi Q; Indulkar AS; Purohit HS; Gao Y; Zhang GGZ; Taylor LS
Mol Pharm; 2023 Jan; 20(1):722-737. PubMed ID: 36545917
[TBL] [Abstract][Full Text] [Related]
11. Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.
Hiew TN; Zemlyanov DY; Taylor LS
Mol Pharm; 2022 Feb; 19(2):392-413. PubMed ID: 34494842
[TBL] [Abstract][Full Text] [Related]
12. Improved dissolution of an enteric polymer and its amorphous solid dispersions by polymer salt formation.
Qi Q; Taylor LS
Int J Pharm; 2022 Jun; 622():121886. PubMed ID: 35661745
[TBL] [Abstract][Full Text] [Related]
13. Dissolution Mechanisms of Amorphous Solid Dispersions: A Close Look at the Dissolution Interface.
Deac A; Qi Q; Indulkar AS; Gao Y; Zhang GGZ; Taylor LS
Mol Pharm; 2023 Apr; 20(4):2217-2234. PubMed ID: 36926898
[TBL] [Abstract][Full Text] [Related]
14. Impact of Drug-Polymer Intermolecular Interactions on Dissolution Performance of Copovidone-Based Amorphous Solid Dispersions.
Que C; Deac A; Zemlyanov DY; Qi Q; Indulkar AS; Gao Y; Zhang GGZ; Taylor LS
Mol Pharm; 2021 Sep; 18(9):3496-3508. PubMed ID: 34319746
[TBL] [Abstract][Full Text] [Related]
15. Theoretical evaluation of supersaturation of amorphous solid dispersion formulations with different drug/polymer combinations using mathematical modeling.
Hirai D; Tsunematsu H; Kimura SI; Itai S; Fukami T; Iwao Y
Int J Pharm; 2022 Sep; 625():122110. PubMed ID: 35970282
[TBL] [Abstract][Full Text] [Related]
16. Complementarity of mDSC, DMA, and DRS Techniques in the Study of
Thayumanasundaram S; Venkatesan TR; Ousset A; Van Hollebeke K; Aerts L; Wübbenhorst M; Van den Mooter G
Mol Pharm; 2022 Jul; 19(7):2299-2315. PubMed ID: 35674392
[TBL] [Abstract][Full Text] [Related]
17. Combining drug salt formation with amorphous solid dispersions - a double edged sword.
Hiew TN; Taylor LS
J Control Release; 2022 Dec; 352():47-60. PubMed ID: 36206947
[TBL] [Abstract][Full Text] [Related]
18. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection.
Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS
Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104
[TBL] [Abstract][Full Text] [Related]
19. Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions.
Figueirêdo CBM; Nadvorny D; Vieira ACQM; Schver GCRM; Soares Sobrinho JL; Rolim Neto PJ; Lee PI; Soares MFR
Eur J Pharm Sci; 2018 Jul; 119():208-218. PubMed ID: 29679707
[TBL] [Abstract][Full Text] [Related]
20. Dissolution Kinetics of Nifedipine-Ionizable Polymer Amorphous Solid Dispersion: Comparison Between Bicarbonate and Phosphate Buffers.
Sakamoto A; Sugano K
Pharm Res; 2021 Dec; 38(12):2119-2127. PubMed ID: 34931285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
